S&P Pharma Dose - Episode 30: Rebates And Pharma Supply Chain | S&P Global Ratings

Name: S&P Pharma Dose - Episode 30: Rebates And Pharma Supply Chain
Uploaded: 2019-06-03T15:21:45.000Z
Duration: T10M5S
Description: Healthcare analysts Tulip Lim and Ji Liu drop in on the S&P Pharma Guy, Arthur Wong, to talk how HHS's proposal to ban rebating from the Medicare market. What's the impact on the ratings of the pharma supply chain players?

In This List

S&P Pharma Dose - Episode 30: Rebates And Pharma Supply Chain

Leveraged Finance & CLOs Uncovered Podcast: The Future of Securitization in Saudi Arabia

COMMENTS

Global Pharmaceutical Companies Ratings Are Unlikely To Be Highly Disrupted By Rising Risks

COMMENTS

Credit FAQ: Retailers' Cyber Attack Recovery Is Slowed By Logistical Scale And Complexity

COMMENTS

Default, Transition, and Recovery: The U.S. Leveraged Loan Default Rate Could Rise To 1.75% Through March 2026

3 Aug, 2018 | 12:00

Listen: S&P Pharma Dose - Episode 30: Rebates And Pharma Supply Chain

Sector Corporates

Healthcare analysts Tulip Lim and Ji Liu drop in on the S&P Pharma Guy, Arthur Wong, to talk how HHS's proposal to ban rebating from the Medicare market. What's the impact on the ratings of the pharma supply chain players?

Sector
Corporates

Create a free account to unlock the article.

Gain access to exclusive research, events and more.

Already have an account? Sign in